TABLE 7.
The impact of Freeze drying on methotrexate nano-formulations with different cryoprotectant (Mannitol and sucrose).
| Status | Parameter | MSX5 | MSX8 | MSX9 |
|---|---|---|---|---|
| Initial | Size (nm) | 165.7 ± 1.85 | 174.6 ± 3.00 | 202.6 ± 1.20 |
| PDI | 0.215 ± 0.010 | 0.227 ± 0.017 | 0.235 ± 0.008 | |
| Without cryoprotectant | Size (nm) | 218.5 ± 16.74 | 242.7 ± 9.78 | 258.5 ± 13.85 |
| PDI | 0.271 ± 0.024 | 0.291 ± 0.013 | 0.243 ± 0.004 | |
| 2% Sucrose | Size (nm) | 249.5 ± 10.7 | 265.3 ± 15.31 | 293.4 ± 16.25 |
| PDI | 0.251 ± 0.02 | 0.316 ± 0.05 | 0.28 ± 0.02 | |
| 4% Sucrose | Size (nm) | 258.6 ± 18.04 | 289.5 ± 16.08 | 306.8 ± 14.38 |
| PDI | 0.423 ± 0.02 | 0.321 ± 0.04 | 0.338 ± 0.02 | |
| 8% Sucrose | Size (nm) | 318.3 ± 12.73 | 322.1 ± 15.69 | 340.9 ± 19.95 |
| PDI | 0.301 ± 0.02 | 0.268 ± 0.05 | 0.297 ± 0.04 | |
| 2% Mannitol | Size (nm) | 184.2 ± 10.30 | 188.9 ± 9.37 | 209.3 ± 11.64 |
| PDI | 0.248 ± 0.03 | 0.173 ± 0.04 | 0.341 ± 0.01 | |
| 4% Mannitol | Size (nm) | 199.2 ± 9.17 | 200.3 ± 14.81 | 226.1 ± 13.70 |
| PDI | 0.339 ± 0.04 | 0.159 ± 0.07 | 0.303 ± 0.02 | |
| 8% Mannitol | Size (nm) | 231.1 ± 15.74 | 239.3 ± 11.95 | 269.4 ± 18.95 |
| PDI | 0.225 ± 0.05 | 0.283 ± 0.05 | 0.199 ± 0.07 |